JAX
Mouse Strain Datasheet - 002507
B6.129S2-Serpine1tm1Mlg/J
Also Known As: PAI-1-
These plasminogen activator inhibitor-1 deficient mice may be useful for studying the role of fibrosis and fibrinolysis in amyloid plaque deposition (Alzheimer's disease), hyperphagia, obesity, injury and muscular dystrophy.
Donating Investigator
Dr. Peter Carmeliet, University of Leuven
Genetic overview
| Genetic Background | Generation |
|---|---|
|
000664 C57BL/6J |
N10F6
|
Serpine1tm1Mlg
| Allele Type | Gene Symbol | Gene Name |
|---|---|---|
| Targeted (Null/Knockout) | Serpine1 | serine (or cysteine) peptidase inhibitor, clade E, member 1 |
Detailed Description
Mice homozygous for this plasminogen activator inhibitor-1 null allele (PAI-1-) are viable and fertile with normal development. Compared to wildtype mice, pulmonary clot lysis is increased in the heterozygote and further increased in the homozygote. Endotoxin induced venous thrombosis is decreased compared to wildtype mice. Thus, disruption of the PAI-1 (Serpine1) gene induces a mild hyperfibrinolytic state. Hemostasis is normal in homozygous mutants.
Development
The plasminogen activator inhibitor-1 (PAI-1 or Serpine1) targeted null mutation was made in the laboratories of Dr. Richard Mulligan (Whitehead Institute for Biomedical Sciences) and of Dr. Peter Carmellet (University of Leuven). A targeting vector was used which resulted in the neomycin-resistant gene replacing all coding sequences. The Serpine1 gene was isolated from a BALB/c genomic library and targeting was done in D3 ES cells.
Control Suggestions
Selected References
- Carmeliet P; Kieckens L; Schoonjans L; Ream B; van Nuffelen A; Prendergast G; Cole M; Bronson R; Collen D; Mulligan RC. 1993. Plasminogen activator inhibitor-1 gene-deficient mice. I. Generation by homologous recombination and characterization. J Clin Invest 92(6):2746-55. PubMed: 8254028MGI: J:39819
Serpine1tm1Mlg
Allele Symbol: Serpine1tm1Mlg
| Allele Name | targeted mutation 1, Richard C Mulligan |
|---|---|
| Allele Type | Targeted (Null/Knockout) |
| Allele Synonym(s) | PAI-1-; Planh1tm1; Serpine1tm1Mg |
| Gene Symbol and Name | Serpine1, serine (or cysteine) peptidase inhibitor, clade E, member 1 |
| Gene Synonym(s) | PAI; PAI-1; PAI1; PAI1A; PLANH1; Pai1; Pai1aa; Planh; Planh1; Planh1; RATPAI1A; plasminogen activator inhibitor, type I |
| Strain of Origin | 129S2/SvPas |
| Chromosome | 5 |
| Molecular Note | A PGK-neomycin resistance cassette replaced all of the Serpine1 coding sequence and part of the promoter region including the transcription initiation site. Northern blot analysis did not detect Serpine1 mRNA in endotoxin-treated homozygous mutant liver. Neither untreated nor endotoxin-treated homozygous mutant kidney produced detectable SERPINE1 immunoreactivity. A monoclonal antibody based immunofunctional assay did not detect protein levels in plasma of endotoxin-treated homozygous mutant mice. |
| Mutations Made By | Dr. Peter Carmeliet, University of Leuven |
Disease Terms
Research Areas By Genotype
This mouse can be used to support research in many areas including:
Genotype: Serpine1tm1Mlg related
- Cancer Research
- Defects in Cell Adhesion Molecules
- Internal/Organ Research
- Wound Healing
- enhanced
- Wound Healing
Mammalian Phenotype Terms by Genotype
Genotype: Serpine1tm1Mlg/Serpine1tm1Mlg
B6.129S2-Serpine1tm1Mlg/J
cardiovascular system phenotype
- cardiac fibrosis
- older mutants develop cardiac fibrosis, however fibrosis is not seen in the liver, spleen, lungs or kidneys and do not develop small vessel disease (MGI Ref ID J:101486)
- heart inflammation
- older mutants exhibit significantly more macrophages in the heart (MGI Ref ID J:101486)
- increased angiogenesis
- aortic vessel explants show increased capillary sprouting in both collagen lattices and Matrigel (MGI Ref ID J:108675)
immune system phenotype
- heart inflammation
- older mutants exhibit significantly more macrophages in the heart (MGI Ref ID J:101486)
- increased susceptibility to bacterial infection
- following infection with S. pneumoniae strain ATCC 6303 (a more virulent strain), mortality is increased (10% survival compared to 45% in wild-type mice) (MGI Ref ID J:124327)
- following infection with S. pneumoniae, acute lung injury and alveolar hemorrhage is enhanced (MGI Ref ID J:124327)
- following infection with live Streptococcus pneumoniae, S. pneumoniae wild-type lysate, and S. pneumoniae pneumolysin (PLY), mice begin to die earlier and are all dead by 5 days post-infection (MGI Ref ID J:124327)
homeostasis/metabolism phenotype
- abnormal enzyme/coenzyme activity
- 3 weeks after BDL, pro-MMP-9 and MMP-9 activities in liver homogenates from mutants are increased significantly compared to wild-type controls (MGI Ref ID J:123733)
- 3 weeks after BDL, urokinase plasminogen activator (uPA) and plasmin activity are not increased in mutants but tissue-type plasminogen activator (tPA) activity is significantly increased relative to wild-type (MGI Ref ID J:123733)
liver/biliary system phenotype
- liver fibrosis
- 3 weeks after bile duct ligation (BDL), hepatic fibrosis is reduced 18-26% compared to wild-type; hepatic collagen content is similar to sham-operated wild-type (MGI Ref ID J:123733)
- liver/biliary system phenotype
- stellate cell activation, TGFbeta-1 and collagen synthesis are similar in mutants and controls before and after bile duct ligation (MGI Ref ID J:123733)
mortality/aging
- increased sensitivity to induced morbidity/mortality
- following infection with S. pneumoniae strain ATCC 6303 (a more virulent strain), mortality is increased (10% survival compared to 45% in wild-type mice) (MGI Ref ID J:124327)
- following infection with live Streptococcus pneumoniae, S. pneumoniae wild-type lysate, and S. pneumoniae pneumolysin (PLY), mice begin to die earlier and are all dead by 5 days post-infection (MGI Ref ID J:124327)
The following phenotype information is associated with a similar, but not exact match to this JAX® Mice strain
Genotype: Serpine1tm1Mlg/Serpine1tm1Mlg
involves: 129S2/SvPas * C57BL/6
growth/size/body region phenotype
- abnormal body weight
- less weight gain on a high fat diet than normal (MGI Ref ID J:87982)
- decreased body weight
- at 2 weeks, mutants remain below initial body weight after turpentine injection-induced weight loss but wild-type mice recover and begin to gain weight around 6-7 days after injection (MGI Ref ID J:133227)
- weight loss
- turpentine injection induces significant weight loss in mutants and wild-type mice in initial 2 days; however, after 2 days, wild-type animals start to recover body weight whereas mutants do not (MGI Ref ID J:133227)
liver/biliary system phenotype
- decreased liver triglyceride level
- lower levels after 12 weeks on a high fat diet (MGI Ref ID J:87982)
integument phenotype
- decreased subcutaneous adipose tissue amount
- subcutaneous white fat pad mass was also reduced (MGI Ref ID J:87982)
immune system phenotype
- abnormal acute inflammation
- C3 peak levels at day 3 are higher than in wild-type (MGI Ref ID J:133227)
- haptoglobin levels do not differ from wild-type at any time after turpentine injection (MGI Ref ID J:133227)
- in mutants after turpentine injection, serum amyloid P and C3 are significantly lower at 24 hours compared to wild-type and display a delayed peak at 3 days after injection (MGI Ref ID J:133227)
- abnormal interleukin level
- local Il6 levels in injured tissue at 8 hours post-injection are lower than in controls (MGI Ref ID J:133227)
- decreased circulating interleukin-6 level
- plasma levels are markedly reduced at 8 hours after turpentine injection (MGI Ref ID J:133227)
- glomerulonephritis
- immune system phenotype
- chemokine levels in injured tissue are similar between mutants and controls, peaking at 1-3 days (MGI Ref ID J:133227)
- increased acute inflammation
- after turpentine injection to hind limb to induce tissue injury, 8 week-old mutants show significantly more local tissue injury compared to controls (MGI Ref ID J:133227)
- treatment resulted in local abscess formation and neutrophilic granulocyte infiltration encapsulated by macrophages and fibroblasts (MGI Ref ID J:133227)
- increased granulocyte number
- relative to controls following turpentine injection (MGI Ref ID J:133227)
- respiratory system inflammation
renal/urinary system phenotype
- glomerular crescent
- higher incidence of fibrin positive crescents (MGI Ref ID J:85989)
- glomerulonephritis
- increased urine protein level
- an earlier enhancement of protein urea (MGI Ref ID J:85989)
cardiovascular system phenotype
- abnormal blood circulation
- decreased angiogenesis
- neovascularization in general is reduced (MGI Ref ID J:65383)
hematopoietic system phenotype
- hematopoietic system phenotype
- bleeding time was normal (MGI Ref ID J:39819)
- increased granulocyte number
- relative to controls following turpentine injection (MGI Ref ID J:133227)
respiratory system phenotype
- abnormal lung morphology
- lung fibrin deposition following bleomycin treatment is almost undetectable compared to treated wild-type mice (MGI Ref ID J:31542)
- no significant bleomycin-induced increase in lung collagen content is detected at 3 weeks posttreatment whereas treated wild-type mice show a significant increase in lung collagen; heterozygous mice are intermediate between null and wild-type in terms of collagen contentcollagen content (MGI Ref ID J:31542)
- respiratory system inflammation
adipose tissue phenotype
- abnormal epididymal fat pad morphology
- after 12 weeks on a high fat diet, epididymal fat pad was only 25% of wild-type (MGI Ref ID J:87982)
- decreased subcutaneous adipose tissue amount
- subcutaneous white fat pad mass was also reduced (MGI Ref ID J:87982)
neoplasm
- neoplasm
- after injection of melanoma cells, number of primary pulmonary metastases post-injection, or tumor burdens initiated by injections of increasing doses of cells do not significantly differ from wild-type controls (MGI Ref ID J:33232)
- no significant differences are observed compared to controls in terms of primary tumor size of footpad tumors induced by foot pad injection with tumor cells at 10, 17, or 21 days post-injection (MGI Ref ID J:33232)
- survival times after foot pad tumor removal are not significantly different among Serpine1-deficient, Serpine1-overexpressing transgenic, or wild-type mice (MGI Ref ID J:33232)
homeostasis/metabolism phenotype
- abnormal energy expenditure
- increased after 12 weeks on a high fat diet (MGI Ref ID J:87982)
- abnormal enzyme/coenzyme activity
- after 8 hours, myeloperoxidase (MPO) activity is higher in mutants in hind limb homogenates than in wild-type (MGI Ref ID J:133227)
- abnormal interleukin level
- local Il6 levels in injured tissue at 8 hours post-injection are lower than in controls (MGI Ref ID J:133227)
- decreased circulating interleukin-6 level
- plasma levels are markedly reduced at 8 hours after turpentine injection (MGI Ref ID J:133227)
- decreased liver triglyceride level
- lower levels after 12 weeks on a high fat diet (MGI Ref ID J:87982)
- decreased triglyceride level
- lower levels in both skeletal muscle and liver after 12 weeks on a high fat diet (MGI Ref ID J:87982)
- enhanced wound healing
- increased body temperature
- increased on a high fat diet (MGI Ref ID J:87982)
- increased oxygen consumption
- after 12 weeks on a high fat diet, oxygen consumption is increased (MGI Ref ID J:87982)
- increased urine protein level
- an earlier enhancement of protein urea (MGI Ref ID J:85989)
Genotype: Serpine1tm1Mlg/Serpine1tm1Mlg
involves: 129S2/SvPas * C57BL/6 * C57BLKS/J
homeostasis/metabolism phenotype
- decreased circulating cholesterol level
- mean levels are significantly lower than in wild-type controls and STZ-treated mutants (MGI Ref ID J:127478)
- homeostasis/metabolism phenotype
- mice do not develop significant albuminuria after 6 months of streptozotocin (STZ) -induced diabetes (MGI Ref ID J:127478)
- hyperglycemia
- in streptozotocin-treated (STZ) mice (to induce diabetes), serum glucose is significantly increased compared to untreated mutant or wild-type controls (MGI Ref ID J:127478)
- increased blood urea nitrogen level
- STZ-treated mutants show elevated BUN levels compared to untreated mice, but levels are comparable to STZ-treated wild-type (MGI Ref ID J:127478)
renal/urinary system phenotype
- abnormal kidney morphology
- total kidney collagen in STZ-treated mice increases only 8% compared to 40% in treated wild-type (MGI Ref ID J:127478)
- abnormal renal glomerulus morphology
- glomerular extracellular matrix (ECM) area is greater than in wild-type controls; however, when expressed as fractional glomerular ECM area, little difference is observed between any genotype (MGI Ref ID J:127478)
- glomerular extracellular matrix (ECM) area is significantly higher compared to controls; after 6 months of STZ-induced diabetes, ECM area is decreased 15% compared to Serpine1 single deficient mice while in STZ-treated wild-type mice, ECM area is increased 64% relative to untreated wild-type miceed 64% relative to untreated wild-type mice (MGI Ref ID J:127478)
Genotype: Serpine1tm1Mlg/Serpine1tm1Mlg
involves: 129S2/SvPas
mortality/aging
- decreased sensitivity to xenobiotic induced morbidity/mortality
- in mice treated with LPS (MGI Ref ID J:229191)
immune system phenotype
- decreased susceptibility to endotoxin shock
- LPS-treated mice exhibit increased survival compared with wild-type mice (MGI Ref ID J:229191)
homeostasis/metabolism phenotype
- decreased sensitivity to xenobiotic induced morbidity/mortality
- in mice treated with LPS (MGI Ref ID J:229191)
References
- Carmeliet P; Kieckens L; Schoonjans L; Ream B; van Nuffelen A; Prendergast G; Cole M; Bronson R; Collen D; Mulligan RC. 1993. Plasminogen activator inhibitor-1 gene-deficient mice. I. Generation by homologous recombination and characterization. J Clin Invest 92(6):2746-55. PubMed: 8254028MGI: J:39819
Additional References
- Carmeliet P; Stassen JM; Schoonjans L; Ream B; van den Oord JJ; De Mol M; Mulligan RC; Collen D. 1993. Plasminogen activator inhibitor-1 gene-deficient mice. II. Effects on hemostasis, thrombosis, and thrombolysis. J Clin Invest 92(6):2756-60. PubMed: 8254029MGI: J:67715
- Chan JC; Duszczyszyn DA; Castellino FJ; Ploplis VA. 2001. Accelerated skin wound healing in plasminogen activator inhibitor-1-deficient mice. Am J Pathol 159(5):1681-8. PubMed: 11696429MGI: J:72394
- Hattori N; Mizuno S; Yoshida Y; Chin K; Mishima M; Sisson TH; Simon RH; Nakamura T; Miyake M. 2004. The plasminogen activation system reduces fibrosis in the lung by a hepatocyte growth factor-dependent mechanism. Am J Pathol 164(3):1091-8. PubMed: 14982862MGI: J:88462
- Ma LJ; Mao SL; Taylor KL; Kanjanabuch T; Guan Y; Zhang Y; Brown NJ; Swift LL; McGuinness OP; Wasserman DH; Vaughan DE; Fogo AB. 2004. Prevention of obesity and insulin resistance in mice lacking plasminogen activator inhibitor 1. Diabetes 53(2):336-46. PubMed: 14747283MGI: J:87982
Additional - Serpine1tm1Mlg related
- Allen GB; Cloutier ME; Larrabee YC; Tetenev K; Smiley ST; Bates JH. 2009. Neither fibrin nor plasminogen activator inhibitor-1 deficiency protects lung function in a mouse model of acute lung injury. Am J Physiol Lung Cell Mol Physiol 296(3):L277-85. PubMed: 19060228MGI: J:146313
- Almholt K; Nielsen BS; Frandsen TL; Brunner N; Dano K; Johnsen M. 2003. Metastasis of transgenic breast cancer in plasminogen activator inhibitor-1 gene-deficient mice. Oncogene 22(28):4389-97. PubMed: 12853975MGI: J:84633
- Ardite E; Perdiguero E; Vidal B; Gutarra S; Serrano AL; Munoz-Canoves P. 2012. PAI-1-regulated miR-21 defines a novel age-associated fibrogenic pathway in muscular dystrophy. J Cell Biol 196(1):163-75. PubMed: 22213800MGI: J:179966
- Arndt PG; Young SK; Worthen GS. 2005. Regulation of lipopolysaccharide-induced lung inflammation by plasminogen activator Inhibitor-1 through a JNK-mediated pathway. J Immunol 175(6):4049-59. PubMed: 16148154MGI: J:116702
- Bajou K; Herkenne S; Thijssen VL; D'Amico S; Nguyen NQ; Bouche A; Tabruyn S; Srahna M; Carabin JY; Nivelles O; Paques C; Cornelissen I; Lion M; Noel A; Gils A; Vinckier S; Declerck PJ; Griffioen AW; Dewerchin M; Martial JA; Carmeliet P; Struman I. 2014. PAI-1 mediates the antiangiogenic and profibrinolytic effects of 16K prolactin. Nat Med 20(7):741-7. PubMed: 24929950MGI: J:227609
- Bajou K; Maillard C; Jost M; Lijnen RH; Gils A; Declerck P; Carmeliet P; Foidart JM; Noel A. 2004. Host-derived plasminogen activator inhibitor-1 (PAI-1) concentration is critical for in vivo tumoral angiogenesis and growth. Oncogene 23(41):6986-90. PubMed: 15286708MGI: J:93782
- Bajou K; Noel A; Gerard RD; Masson V; Brunner N; Holst-Hansen C; Skobe M; Fusenig NE; Carmeliet P; Collen D; Foidart JM. 1998. Absence of host plasminogen activator inhibitor 1 prevents cancer invasion and vascularization. Nat Med 4(8):923-8. PubMed: 9701244MGI: J:49535
- Bajou K; Peng H; Laug WE; Maillard C; Noel A; Foidart JM; Martial JA; DeClerck YA. 2008. Plasminogen activator inhibitor-1 protects endothelial cells from FasL-mediated apoptosis. Cancer Cell 14(4):324-34. PubMed: 18835034MGI: J:140088
- Bajt ML; Yan HM; Farhood A; Jaeschke H. 2008. Plasminogen activator inhibitor-1 limits liver injury and facilitates regeneration after acetaminophen overdose. Toxicol Sci 104(2):419-27. PubMed: 18469330MGI: J:139782
- Balsara RD; Castellino FJ; Ploplis VA. 2006. A novel function of plasminogen activator inhibitor-1 in modulation of the AKT pathway in wild-type and plasminogen activator inhibitor-1-deficient endothelial cells. J Biol Chem 281(32):22527-36. PubMed: 16785241MGI: J:116488
- Basu A; Menicucci G; Maestas J; Das A; McGuire P. 2009. Plasminogen activator inhibitor-1 (PAI-1) facilitates retinal angiogenesis in a model of oxygen-induced retinopathy. Invest Ophthalmol Vis Sci 50(10):4974-81. PubMed: 19443721MGI: J:154543
- Bauman KA; Wettlaufer SH; Okunishi K; Vannella KM; Stoolman JS; Huang SK; Courey AJ; White ES; Hogaboam CM; Simon RH; Toews GB; Sisson TH; Moore BB; Peters-Golden M. 2010. The antifibrotic effects of plasminogen activation occur via prostaglandin E2 synthesis in humans and mice. J Clin Invest 120(6):1950-60. PubMed: 20501949MGI: J:161628
- Beier JI; Kaiser JP; Guo L; Martinez-Maldonado M; Arteel GE. 2011. Plasminogen activator inhibitor-1 deficient mice are protected from angiotensin II-induced fibrosis. Arch Biochem Biophys 510(1):19-26. PubMed: 21501583MGI: J:177896
- Bergheim I; Guo L; Davis MA; Duveau I; Arteel GE. 2006. Critical role of plasminogen activator inhibitor-1 in cholestatic liver injury and fibrosis. J Pharmacol Exp Ther 316(2):592-600. PubMed: 16221737MGI: J:136744
- Bhandary YP; Shetty SK; Marudamuthu AS; Ji HL; Neuenschwander PF; Boggaram V; Morris GF; Fu J; Idell S; Shetty S. 2013. Regulation of Lung Injury and Fibrosis by p53-Mediated Changes in Urokinase and Plasminogen Activator Inhibitor-1. Am J Pathol 183(1):131-43. PubMed: 23665346MGI: J:197439
- Boulaftali Y; Adam F; Venisse L; Ollivier V; Richard B; Taieb S; Monard D; Favier R; Alessi MC; Bryckaert M; Arocas V; Jandrot-Perrus M; Bouton MC. 2010. Anticoagulant and antithrombotic properties of platelet protease nexin-1. Blood 115(1):97-106. PubMed: 19855083MGI: J:155899
- Brodsky S; Chen J; Lee A; Akassoglou K; Norman J; Goligorsky MS. 2001. Plasmin-dependent and -independent effects of plasminogen activators and inhibitor-1 on ex vivo angiogenesis. Am J Physiol Heart Circ Physiol 281(4):H1784-92. PubMed: 11557572MGI: J:108675
- Bruyere F; Melen-Lamalle L; Blacher S; Detry B; Masset A; Lecomte J; Lambert V; Maillard C; Hoyer-Hansen G; Lund LR; Foidart JM; Noel A. 2010. Does plasminogen activator inhibitor-1 drive lymphangiogenesis? PLoS One 5(3):e9653. PubMed: 20300183MGI: J:158909
- Carmeliet P; Stassen JM; Schoonjans L; Ream B; van den Oord JJ; De Mol M; Mulligan RC; Collen D. 1993. Plasminogen activator inhibitor-1 gene-deficient mice. II. Effects on hemostasis, thrombosis, and thrombolysis. J Clin Invest 92(6):2756-60. PubMed: 8254029MGI: J:67715
- Chan JC; Duszczyszyn DA; Castellino FJ; Ploplis VA. 2001. Accelerated skin wound healing in plasminogen activator inhibitor-1-deficient mice. Am J Pathol 159(5):1681-8. PubMed: 11696429MGI: J:72394
- Cho E; Lee KJ; Seo JW; Byun CJ; Chung SJ; Suh DC; Carmeliet P; Koh JY; Kim JS; Lee JY. 2012. Neuroprotection by urokinase plasminogen activator in the hippocampus. Neurobiol Dis 46(1):215-24. PubMed: 22293605MGI: J:182295
- Chuang-Tsai S; Sisson TH; Hattori N; Tsai CG; Subbotina NM; Hanson KE; Simon RH. 2003. Reduction in fibrotic tissue formation in mice genetically deficient in plasminogen activator inhibitor-1. Am J Pathol 163(2):445-52. PubMed: 12875966MGI: J:109418
- Collins SJ; Alexander SL; Lopez-Guisa JM; Cai X; Maruvada R; Chua SC; Zhang G; Okamura DM; Matsuo S; Eddy AA. 2006. Plasminogen activator inhibitor-1 deficiency has renal benefits but some adverse systemic consequences in diabetic mice. Nephron Exp Nephrol 104(1):e23-34. PubMed: 16735799MGI: J:127478
- Courey AJ; Horowitz JC; Kim KK; Koh TJ; Novak ML; Subbotina N; Warnock M; Xue B; Cunningham AK; Lin Y; Goldklang MP; Simon RH; Lawrence DA; Sisson TH. 2011. The vitronectin-binding function of PAI-1 exacerbates lung fibrosis in mice. Blood 118(8):2313-21. PubMed: 21734232MGI: J:177097
- De Taeye BM; Novitskaya T; Gleaves L; Covington JW; Vaughan DE. 2006. Bone marrow plasminogen activator inhibitor-1 influences the development of obesity. J Biol Chem 281(43):32796-805. PubMed: 16931518MGI: J:117279
- Dhahri D; Sato-Kusubata K; Ohki-Koizumi M; Nishida C; Tashiro Y; Munakata S; Shimazu H; Salama Y; Eiamboonsert S; Nakauchi H; Hattori K; Heissig B. 2016. Fibrinolytic crosstalk with endothelial cells expands murine mesenchymal stromal cells. Blood 128(8):1063-75. PubMed: 27283026MGI: J:236265
- DiMusto PD; Lu G; Ghosh A; Roelofs KJ; Su G; Zhao Y; Lau CL; Sadiq O; McEvoy B; Laser A; Diaz JA; Wakefield TW; Henke PK; Eliason JL; Upchurch GR Jr. 2012. Increased PAI-1 in females compared with males is protective for abdominal aortic aneurysm formation in a rodent model. Am J Physiol Heart Circ Physiol 302(7):H1378-86. PubMed: 22307671MGI: J:186579
- Dittmann M; Hoffmann HH; Scull MA; Gilmore RH; Bell KL; Ciancanelli M; Wilson SJ; Crotta S; Yu Y; Flatley B; Xiao JW; Casanova JL; Wack A; Bieniasz PD; Rice CM. 2015. A serpin shapes the extracellular environment to prevent influenza A virus maturation. Cell 160(4):631-43. PubMed: 25679759MGI: J:219872
- Dougherty KM; Pearson JM; Yang AY; Westrick RJ; Baker MS; Ginsburg D. 1999. The plasminogen activator inhibitor-2 gene is not required for normal murine development or survival. Proc Natl Acad Sci U S A 96(2):686-91. PubMed: 9892694MGI: J:52283
- Ebrahimian TG; Squiban C; Roque T; Lugo-Martinez H; Hneino M; Buard V; Gourmelon P; Benderitter M; Milliat F; Tamarat R. 2012. Plasminogen activator inhibitor-1 controls bone marrow-derived cells therapeutic effect through MMP9 signaling: role in physiological and pathological wound healing. Stem Cells 30(7):1436-46. PubMed: 22570200MGI: J:194569
- Eitzman DT; Krauss JC; Shen T; Cui J; Ginsburg. 1996. Lack of plasminogen activator inhibitor-1 effect in a transgenic mouse model of metastatic melanoma. Blood 87(11):4718-22. PubMed: 8639841MGI: J:33232
- Eitzman DT; McCoy RD; Zheng X; Fay WP; Shen T; Ginsburg D; Simon RH. 1996. Bleomycin-induced pulmonary fibrosis in transgenic mice that either lack or overexpress the murine plasminogen activator inhibitor-1 gene. J Clin Invest 97(1):232-7. PubMed: 8550840MGI: J:31542
- Eitzman DT; Westrick RJ; Nabel EG; Ginsburg D. 2000. Plasminogen activator inhibitor-1 and vitronectin promote vascular thrombosis in mice. Blood 95(2):577-80. PubMed: 10627465MGI: J:110259
- Eitzman DT; Westrick RJ; Xu Z; Tyson J; Ginsburg D. 2000. Plasminogen activator inhibitor-1 deficiency protects against atherosclerosis progression in the mouse carotid artery. Blood 96(13):4212-5. PubMed: 11110693MGI: J:106740
- Eren M; Boe AE; Murphy SB; Place AT; Nagpal V; Morales-Nebreda L; Urich D; Quaggin SE; Budinger GR; Mutlu GM; Miyata T; Vaughan DE. 2014. PAI-1-regulated extracellular proteolysis governs senescence and survival in Klotho mice. Proc Natl Acad Sci U S A 111(19):7090-5. PubMed: 24778222MGI: J:211073
- Fang H; Placencio VR; DeClerck YA. 2012. Protumorigenic activity of plasminogen activator inhibitor-1 through an antiapoptotic function. J Natl Cancer Inst 104(19):1470-84. PubMed: 22984202MGI: J:191274
- Fen Li C; Kandel C; Baliko F; Nadesan P; Brunner N; Alman BA. 2005. Plasminogen activator inhibitor-1 (PAI-1) modifies the formation of aggressive fibromatosis (desmoid tumor). Oncogene 24(9):1615-24. PubMed: 15674349MGI: J:96994
- Ghosh AK; Bradham WS; Gleaves LA; De Taeye B; Murphy SB; Covington JW; Vaughan DE. 2010. Genetic deficiency of plasminogen activator inhibitor-1 promotes cardiac fibrosis in aged mice: involvement of constitutive transforming growth factor-beta signaling and endothelial-to-mesenchymal transition. Circulation 122(12):1200-9. PubMed: 20823384MGI: J:179489
- Ghosh AK; Murphy SB; Kishore R; Vaughan DE. 2013. Global gene expression profiling in PAI-1 knockout murine heart and kidney: molecular basis of cardiac-selective fibrosis. PLoS One 8(5):e63825. PubMed: 23724005MGI: J:200713
- Gupta KK; Donahue DL; Sandoval-Cooper MJ; Castellino FJ; Ploplis VA. 2015. Abrogation of plasminogen activator inhibitor-1-vitronectin interaction ameliorates acute kidney injury in murine endotoxemia. PLoS One 10(3):e0120728. PubMed: 25799354MGI: J:229191
- Gupta KK; Xu Z; Castellino FJ; Ploplis VA. 2016. Plasminogen activator inhibitor-1 stimulates macrophage activation through Toll-like Receptor-4. Biochem Biophys Res Commun 477(3):503-8. PubMed: 27317488MGI: J:236488
- Gutierrez LS; Schulman A; Brito-Robinson T; Noria F; Ploplis VA; Castellino FJ. 2000. Tumor development is retarded in mice lacking the gene for urokinase-type plasminogen activator or its inhibitor, plasminogen activator inhibitor-1 Cancer Res 60(20):5839-47. PubMed: 11059781MGI: J:65383
- Harslund J; Nielsen OL; Brunner N; Offenberg H. 2007. Gender-dependent physiological implications of combined PAI-1 and TIMP-1 gene deficiency characterized in a mouse model. Am J Physiol Regul Integr Comp Physiol 293(4):R1630-9. PubMed: 17652357MGI: J:145130
- Hattori N; Degen JL; Sisson TH; Liu H; Moore BB; Pandrangi RG; Simon RH; Drew AF. 2000. Bleomycin-induced pulmonary fibrosis in fibrinogen-null mice J Clin Invest 106(11):1341-50. PubMed: 11104787MGI: J:66093
- Hattori N; Mizuno S; Yoshida Y; Chin K; Mishima M; Sisson TH; Simon RH; Nakamura T; Miyake M. 2004. The plasminogen activation system reduces fibrosis in the lung by a hepatocyte growth factor-dependent mechanism. Am J Pathol 164(3):1091-8. PubMed: 14982862MGI: J:88462
- Heberlein KR; Straub AC; Best AK; Greyson MA; Looft-Wilson RC; Sharma PR; Meher A; Leitinger N; Isakson BE. 2010. Plasminogen activator inhibitor-1 regulates myoendothelial junction formation. Circ Res 106(6):1092-102. PubMed: 20133900MGI: J:170864
- Hertig A; Berrou J; Allory Y; Breton L; Commo F; Costa De Beauregard MA; Carmeliet P; Rondeau E. 2003. Type 1 plasminogen activator inhibitor deficiency aggravates the course of experimental glomerulonephritis through overactivation of transforming growth factor beta. FASEB J 17(13):1904-6. PubMed: 12897066MGI: J:85989
- Hijazi N; Abu Fanne R; Abramovitch R; Yarovoi S; Higazi M; Abdeen S; Basheer M; Maraga E; Cines DB; Higazi AA. 2015. Endogenous plasminogen activators mediate progressive intracerebral hemorrhage after traumatic brain injury in mice. Blood 125(16):2558-67. PubMed: 25673638MGI: J:222043
- Hovius JW; Bijlsma MF; van der Windt GJ; Wiersinga WJ; Boukens BJ; Coumou J; Oei A; de Beer R; de Vos AF; van 't Veer C; van Dam AP; Wang P; Fikrig E; Levi MM; Roelofs JJ; van der Poll T. 2009. The urokinase receptor (uPAR) facilitates clearance of Borrelia burgdorferi. PLoS Pathog 5(5):e1000447. PubMed: 19461880MGI: J:162185
- Ibrahim AA; Yahata T; Onizuka M; Dan T; Van Ypersele De Strihou C; Miyata T; Ando K. 2014. Inhibition of plasminogen activator inhibitor type-1 activity enhances rapid and sustainable hematopoietic regeneration. Stem Cells 32(4):946-58. PubMed: 24155177MGI: J:210192
- Ji Y; Strawn TL; Grunz EA; Stevenson MJ; Lohman AW; Lawrence DA; Fay WP. 2011. Multifaceted role of plasminogen activator inhibitor-1 in regulating early remodeling of vein bypass grafts. Arterioscler Thromb Vasc Biol 31(8):1781-7. PubMed: 21571686MGI: J:191860
- Jost M; Maillard C; Lecomte J; Lambert V; Tjwa M; Blaise P; Alvarez Gonzalez ML; Bajou K; Blacher S; Motte P; Humblet C; Defresne MP; Thiry M; Frankenne F; Gothot A; Carmeliet P; Rakic JM; Foidart JM; Noel A. 2007. Tumoral and choroidal vascularization: differential cellular mechanisms involving plasminogen activator inhibitor type I. Am J Pathol 171(4):1369-80. PubMed: 17717143MGI: J:125522
- Kanuri G; Spruss A; Wagnerberger S; Bischoff SC; Bergheim I. 2011. Fructose-induced steatosis in mice: role of plasminogen activator inhibitor-1, microsomal triglyceride transfer protein and NKT cells. Lab Invest 91(6):885-95. PubMed: 21423135MGI: J:172001
- Kawasaki T; Dewerchin M; Lijnen HR; Vermylen J; Hoylaerts MF. 2000. Vascular release of plasminogen activator inhibitor-1 impairs fibrinolysis during acute arterial thrombosis in mice. Blood 96(1):153-60. PubMed: 10891445MGI: J:63087
- Kawasaki T; Dewerchin M; Lijnen HR; Vreys I; Vermylen J; Hoylaerts MF. 2001. Mouse carotid artery ligation induces platelet-leukocyte-dependent luminal fibrin, required for neointima development. Circ Res 88(2):159-66. PubMed: 11157667MGI: J:115383
- Keller TT; van der Sluijs KF; de Kruif MD; Gerdes VE; Meijers JC; Florquin S; van der Poll T; van Gorp EC; Brandjes DP; Buller HR; Levi M. 2006. Effects on coagulation and fibrinolysis induced by influenza in mice with a reduced capacity to generate activated protein C and a deficiency in plasminogen activator inhibitor type 1. Circ Res 99(11):1261-9. PubMed: 17068293MGI: J:129084
- Kenny S; Gamble J; Lyons S; Vlatkovic N; Dimaline R; Varro A; Dockray GJ. 2013. Gastric expression of plasminogen activator inhibitor (PAI)-1 is associated with hyperphagia and obesity in mice. Endocrinology 154(2):718-26. PubMed: 23254194MGI: J:194605
- Kenny S; Steele I; Lyons S; Moore AR; Murugesan SV; Tiszlavicz L; Dimaline R; Pritchard DM; Varro A; Dockray GJ. 2013. The role of plasminogen activator inhibitor-1 in gastric mucosal protection. Am J Physiol Gastrointest Liver Physiol 304(9):G814-22. PubMed: 23494120MGI: J:196455
- Koh TJ; Bryer SC; Pucci AM; Sisson TH. 2005. Mice deficient in plasminogen activator inhibitor-1 have improved skeletal muscle regeneration. Am J Physiol Cell Physiol 289(1):C217-23. PubMed: 15716324MGI: J:104684
- Koschnick S; Konstantinides S; Schafer K; Crain K; Loskutoff DJ. 2005. Thrombotic phenotype of mice with a combined deficiency in plasminogen activator inhibitor 1 and vitronectin. J Thromb Haemost 3(10):2290-5. PubMed: 16194205MGI: J:114352
- Krag S; Danielsen CC; Carmeliet P; Nyengaard J; Wogensen L. 2005. Plasminogen activator inhibitor-1 gene deficiency attenuates TGF-beta1-induced kidney disease. Kidney Int 68(6):2651-66. PubMed: 16316341MGI: J:116902
- Kremen M; Krishnan R; Emery I; Hu JH; Slezicki KI; Wu A; Qian K; Du L; Plawman A; Stempien-Otero A; Dichek DA. 2008. Plasminogen mediates the atherogenic effects of macrophage-expressed urokinase and accelerates atherosclerosis in apoE-knockout mice. Proc Natl Acad Sci U S A 105(44):17109-14. PubMed: 18957535MGI: J:144061
- Kuramoto E; Nishiuma T; Kobayashi K; Yamamoto M; Kono Y; Funada Y; Kotani Y; Sisson TH; Simon RH; Nishimura Y. 2009. Inhalation of urokinase-type plasminogen activator reduces airway remodeling in a murine asthma model. Am J Physiol Lung Cell Mol Physiol 296(3):L337-46. PubMed: 19098125MGI: J:146567
- Labied S; Blacher S; Carmeliet P; Noel A; Frankenne F; Foidart JM; Munaut C. 2011. Transient reduction of placental angiogenesis in PAI-1-deficient mice. Physiol Genomics 43(4):188-98. PubMed: 21119013MGI: J:220437
- Lambert V; Munaut C; Noel A; Frankenne F; Bajou K; Gerard R; Carmeliet P; Defresne MP; Foidart JM; Rakic JM. 2001. Influence of plasminogen activator inhibitor type 1 on choroidal neovascularization. FASEB J 15(6):1021-7. PubMed: 11292663MGI: J:120446
- Lazar MH; Christensen PJ; Du M; Yu B; Subbotina NM; Hanson KE; Hansen JM; White ES; Simon RH; Sisson TH. 2004. Plasminogen activator inhibitor-1 impairs alveolar epithelial repair by binding to vitronectin. Am J Respir Cell Mol Biol 31(6):672-8. PubMed: 15308506MGI: J:104660
- Leonardsson G; Peng XR; Liu K; Nordstrom L; Carmeliet P; Mulligan R; Collen D; Ny T. 1995. Ovulation efficiency is reduced in mice that lack plasminogen activator gene function: functional redundancy among physiological plasminogen activators. Proc Natl Acad Sci U S A 92(26):12446-50. PubMed: 8618918MGI: J:31086
- Liang X; Kanjanabuch T; Mao SL; Hao CM; Tang YW; Declerck PJ; Hasty AH; Wasserman DH; Fogo AB; Ma LJ. 2006. Plasminogen activator inhibitor-1 modulates adipocyte differentiation. Am J Physiol Endocrinol Metab 290(1):E103-E113. PubMed: 16144810MGI: J:115737
- Lim JH; Stirling B; Derry J; Koga T; Jono H; Woo CH; Xu H; Bourne P; Ha UH; Ishinaga H; Xu H; Andalibi A; Feng XH; Zhu H; Huang Y; Zhang W; Weng X; Yan C; Yin Z; Briles DE; Davis RJ; Flavell RA; Li JD. 2007. Tumor Suppressor CYLD Regulates Acute Lung Injury in Lethal Streptococcus pneumoniae Infections. Immunity 27(2):349-60. PubMed: 17723219MGI: J:124327
- Liu RM; van Groen T; Katre A; Cao D; Kadisha I; Ballinger C; Wang L; Carroll SL; Li L. 2011. Knockout of plasminogen activator inhibitor 1 gene reduces amyloid beta peptide burden in a mouse model of Alzheimer's disease. Neurobiol Aging 32(6):1079-89. PubMed: 19604604MGI: J:173735
- Luo D; Lin JS; Parent MA; Mullarky-Kanevsky I; Szaba FM; Kummer LW; Duso DK; Tighe M; Hill J; Gruber A; Mackman N; Gailani D; Smiley ST. 2013. Fibrin Facilitates Both Innate and T Cell-Mediated Defense against Yersinia pestis. J Immunol 190(8):4149-61. PubMed: 23487423MGI: J:194888
- Luo D; Szaba FM; Kummer LW; Plow EF; Mackman N; Gailani D; Smiley ST. 2011. Protective roles for fibrin, tissue factor, plasminogen activator inhibitor-1, and thrombin activatable fibrinolysis inhibitor, but not factor XI, during defense against the gram-negative bacterium Yersinia enterocolitica. J Immunol 187(4):1866-76. PubMed: 21724997MGI: J:179174
- Luttun A; Lupu F; Storkebaum E; Hoylaerts MF; Moons L; Crawley J; Bono F; Poole AR; Tipping P; Herbert JM; Collen D; Carmeliet P. 2002. Lack of plasminogen activator inhibitor-1 promotes growth and abnormal matrix remodeling of advanced atherosclerotic plaques in apolipoprotein E-deficient mice. Arterioscler Thromb Vasc Biol 22(3):499-505. PubMed: 11884297MGI: J:102938
- Ma J; Weisberg A; Griffin JP; Vaughan DE; Fogo AB; Brown NJ. 2006. Plasminogen activator inhibitor-1 deficiency protects against aldosterone-induced glomerular injury. Kidney Int 69(6):1064-72. PubMed: 16528256MGI: J:136504
- Ma LJ; Mao SL; Taylor KL; Kanjanabuch T; Guan Y; Zhang Y; Brown NJ; Swift LL; McGuinness OP; Wasserman DH; Vaughan DE; Fogo AB. 2004. Prevention of obesity and insulin resistance in mice lacking plasminogen activator inhibitor 1. Diabetes 53(2):336-46. PubMed: 14747283MGI: J:87982
- Maillard CM; Bouquet C; Petitjean MM; Mestdagt M; Frau E; Jost M; Masset AM; Opolon PH; Beermann F; Abitbol MM; Foidart JM; Perricaudet MJ; Noel AC. 2008. Reduction of brain metastases in plasminogen activator inhibitor-1-deficient mice with transgenic ocular tumors. Carcinogenesis 29(11):2236-42. PubMed: 18753414MGI: J:142463
- Mao L; Kawao N; Tamura Y; Okumoto K; Okada K; Yano M; Matsuo O; Kaji H. 2014. Plasminogen activator inhibitor-1 is involved in impaired bone repair associated with diabetes in female mice. PLoS One 9(3):e92686. PubMed: 24651693MGI: J:215068
- Marudamuthu AS; Bhandary YP; Shetty SK; Fu J; Sathish V; Prakash Y; Shetty S. 2015. Role of the Urokinase-Fibrinolytic System in Epithelial-Mesenchymal Transition during Lung Injury. Am J Pathol 185(1):55-68. PubMed: 25447049MGI: J:216959
- Masset A; Maillard C; Sounni NE; Jacobs N; Bruyere F; Delvenne P; Tacke M; Reinheckel T; Foidart JM; Coussens LM; Noel A. 2011. Unimpeded skin carcinogenesis in K14-HPV16 transgenic mice deficient for plasminogen activator inhibitor. Int J Cancer 128(2):283-93. PubMed: 20232379MGI: J:166571
- Matsushita M; Yamamoto T; Nishioka K. 2005. Plasminogen activator inhibitor-1 is elevated, but not essential, in the development of bleomycin-induced murine scleroderma. Clin Exp Immunol 139(3):429-38. PubMed: 15730388MGI: J:96321
- McMahon GA; Petitclerc E; Stefansson S; Smith E; Wong MK; Westrick RJ; Ginsburg D; Brooks PC; Lawrence DA. 2001. Plasminogen activator inhibitor-1 regulates tumor growth and angiogenesis. J Biol Chem 276(36):33964-8. PubMed: 11441025MGI: J:120509
- Milliat F; Sabourin JC; Tarlet G; Holler V; Deutsch E; Buard V; Tamarat R; Atfi A; Benderitter M; Francois A. 2008. Essential role of plasminogen activator inhibitor type-1 in radiation enteropathy. Am J Pathol 172(3):691-701. PubMed: 18276785MGI: J:132273
- Miyamoto S; Hattori N; Senoo T; Onari Y; Iwamoto H; Kanehara M; Ishikawa N; Fujitaka K; Haruta Y; Murai H; Yokoyama A; Kohno N. 2011. Intra-airway administration of small interfering RNA targeting plasminogen activator inhibitor-1 attenuates allergic asthma in mice. Am J Physiol Lung Cell Mol Physiol 301(6):L908-16. PubMed: 21926267MGI: J:180018
- Mollmark JI; Park AJ; Kim J; Wang TZ; Katzenell S; Shipman SL; Zagorchev LG; Simons M; Mulligan-Kehoe MJ. 2012. Fibroblast growth factor-2 is required for vasa vasorum plexus stability in hypercholesterolemic mice. Arterioscler Thromb Vasc Biol 32(11):2644-51. PubMed: 22982464MGI: J:207880
- Moriwaki H; Stempien-Otero A; Kremen M; Cozen AE; Dichek DA. 2004. Overexpression of urokinase by macrophages or deficiency of plasminogen activator inhibitor type 1 causes cardiac fibrosis in mice. Circ Res 95(6):637-44. PubMed: 15297377MGI: J:101486
- Nagai N; De Mol M; Lijnen HR; Carmeliet P; Collen D. 1999. Role of plasminogen system components in focal cerebral ischemic infarction: a gene targeting and gene transfer study in mice. Circulation 99(18):2440-4. PubMed: 10318667MGI: J:55243
- Narasaki R; Xu Z; Liang Z; Fung LC; Donahue D; Castellino FJ; Ploplis VA. 2012. The vitronectin-binding domain of plasminogen activator inhibitor-1 plays an important functional role in lipopolysaccharide-induced lethality in mice. J Thromb Haemost 10(12):2618-21. PubMed: 23082983MGI: J:230643
- Nicholas SB; Aguiniga E; Ren Y; Kim J; Wong J; Govindarajan N; Noda M; Wang W; Kawano Y; Collins A; Hsueh WA. 2005. Plasminogen activator inhibitor-1 deficiency retards diabetic nephropathy. Kidney Int 67(4):1297-307. PubMed: 15780082MGI: J:110122
- Nishiuma T; Sisson TH; Subbotina N; Simon RH. 2004. Localization of plasminogen activator activity within normal and injured lungs by in situ zymography. Am J Respir Cell Mol Biol 31(5):552-8. PubMed: 15284078MGI: J:103595
- Oda T; Jung YO; Kim HS; Cai X; Lopez-Guisa JM; Ikeda Y; Eddy AA. 2001. PAI-1 deficiency attenuates the fibrogenic response to ureteral obstruction. Kidney Int 60(2):587-96. PubMed: 11473641MGI: J:103959
- Oh CK; Ariue B; Alban RF; Shaw B; Cho SH. 2002. PAI-1 promotes extracellular matrix deposition in the airways of a murine asthma model. Biochem Biophys Res Commun 294(5):1155-60. PubMed: 12074598MGI: J:113534
- Omouendze PL; Henry VJ; Porte B; Dupre N; Carmeliet P; Gonzalez BJ; Marret S; Leroux P. 2013. Hypoxia-ischemia or excitotoxin-induced tissue plasminogen activator- dependent gelatinase activation in mice neonate brain microvessels. PLoS One 8(8):e71263. PubMed: 23940734MGI: J:205906
- Osterholzer JJ; Christensen PJ; Lama V; Horowitz JC; Hattori N; Subbotina N; Cunningham A; Lin Y; Murdock BJ; Morey RE; Olszewski MA; Lawrence DA; Simon RH; Sisson TH. 2012. PAI-1 promotes the accumulation of exudate macrophages and worsens pulmonary fibrosis following type II alveolar epithelial cell injury. J Pathol 228(2):170-80. PubMed: 22262246MGI: J:188470
- Otsuka G; Agah R; Frutkin AD; Wight TN; Dichek DA. 2006. Transforming growth factor beta 1 induces neointima formation through plasminogen activator inhibitor-1-dependent pathways. Arterioscler Thromb Vasc Biol 26(4):737-43. PubMed: 16373605MGI: J:127967
- Otsuka G; Stempien-Otero A; Frutkin AD; Dichek DA. 2007. Mechanisms of TGF-beta1-induced intimal growth: plasminogen-independent activities of plasminogen activator inhibitor-1 and heterogeneous origin of intimal cells. Circ Res 100(9):1300-7. PubMed: 17431190MGI: J:137777
- Pinsky DJ; Liao H; Lawson CA; Yan SF; Chen J; Carmeliet P; Loskutoff DJ; Stern DM. 1998. Coordinated induction of plasminogen activator inhibitor-1 (PAI-1) and inhibition of plasminogen activator gene expression by hypoxia promotes pulmonary vascular fibrin deposition. J Clin Invest 102(5):919-28. PubMed: 9727060MGI: J:112025
- Ploplis VA; Cornelissen I; Sandoval-Cooper MJ; Weeks L; Noria FA; Castellino FJ. 2001. Remodeling of the vessel wall after copper-induced injury is highly attenuated in mice with a total deficiency of plasminogen activator inhibitor-1. Am J Pathol 158(1):107-17. PubMed: 11141484MGI: J:67531
- Renckens R; Pater JM; van der Poll T. 2006. Plasminogen activator inhibitor type-1-deficient mice have an enhanced IFN-gamma response to lipopolysaccharide and staphylococcal enterotoxin B. J Immunol 177(11):8171-6. PubMed: 17114493MGI: J:140679
- Renckens R; Roelofs JJ; Bonta PI; Florquin S; de Vries CJ; Levi M; Carmeliet P; van't Veer C; van der Poll T. 2007. Plasminogen activator inhibitor type 1 is protective during severe Gram-negative pneumonia. Blood 109(4):1593-601. PubMed: 17032919MGI: J:144462
- Renckens R; Roelofs JJ; de Waard V; Florquin S; Lijnen HR; Carmeliet P; van der Poll T. 2005. The role of plasminogen activator inhibitor type 1 in the inflammatory response to local tissue injury. J Thromb Haemost 3(5):1018-25. PubMed: 15869599MGI: J:133227
- Rijneveld AW; Florquin S; Bresser P; Levi M; De Waard V; Lijnen R; Van Der Zee JS; Speelman P; Carmeliet P; Van Der Poll T. 2003. Plasminogen activator inhibitor type-1 deficiency does not influence the outcome of murine pneumococcal pneumonia. Blood 102(3):934-9. PubMed: 12702502MGI: J:115706
- Roelofs JJ; Teske GJ; Bonta PI; de Vries CJ; Meijers JC; Weening JJ; van der Poll T; Florquin S. 2009. Plasminogen activator inhibitor-1 regulates neutrophil influx during acute pyelonephritis. Kidney Int 75(1):52-9. PubMed: 18800031MGI: J:145639
- Rossignol P; Luttun A; Martin-Ventura JL; Lupu F; Carmeliet P; Collen D; Angles-Cano E; Lijnen HR. 2006. Plasminogen activation: a mediator of vascular smooth muscle cell apoptosis in atherosclerotic plaques. J Thromb Haemost 4(3):664-70. PubMed: 16460449MGI: J:135792
- Savov JD; Brass DM; Berman KG; McElvania E; Schwartz DA. 2003. Fibrinolysis in LPS-induced chronic airway disease. Am J Physiol Lung Cell Mol Physiol 285(4):L940-8. PubMed: 12818888MGI: J:108631
- Schaefer U; Machida T; Vorlova S; Strickland S; Levi R. 2006. The plasminogen activator system modulates sympathetic nerve function. J Exp Med 203(9):2191-200. PubMed: 16940168MGI: J:124557
- Schafer K; Fujisawa K; Konstantinides S; Loskutoff DJ. 2001. Disruption of the plasminogen activator inhibitor 1 gene reduces the adiposity and improves the metabolic profile of genetically obese and diabetic ob/ob mice. FASEB J 15(10):1840-2. PubMed: 11481248MGI: J:70695
- Scroyen I; Christiaens V; Lijnen HR. 2007. No functional role of plasminogen activator inhibitor-1 in murine adipogenesis or adipocyte differentiation. J Thromb Haemost 5(1):139-45. PubMed: 17067365MGI: J:135923
- Sejima T; Madoiwa S; Mimuro J; Sugo T; Okada K; Ueshima S; Matsuo O; Ishida T; Ichimura K; Sakata Y. 2005. Protection of plasminogen activator inhibitor-1-deficient mice from nasal allergy. J Immunol 174(12):8135-43. PubMed: 15944322MGI: J:100893
- Shah C; Yang G; Lee I; Bielawski J; Hannun YA; Samad F. 2008. Protection from high fat diet-induced increase in ceramide in mice lacking plasminogen activator inhibitor 1. J Biol Chem 283(20):13538-48. PubMed: 18359942MGI: J:137080
- Shetty SK; Tiwari N; Marudamuthu AS; Puthusseri B; Bhandary YP; Fu J; Levin J; Idell S; Shetty S. 2017. p53 and miR-34a Feedback Promotes Lung Epithelial Injury and Pulmonary Fibrosis. Am J Pathol 187(5):1016-1034. PubMed: 28273432MGI: J:241943
- Sisson TH; Nguyen MH; Yu B; Novak ML; Simon RH; Koh TJ. 2009. Urokinase-type plasminogen activator increases hepatocyte growth factor activity required for skeletal muscle regeneration. Blood 114(24):5052-61. PubMed: 19812386MGI: J:154983
- Sjoland H; Eitzman DT; Gordon D; Westrick R; Nabel EG; Ginsburg D. 2000. Atherosclerosis progression in LDL receptor-deficient and apolipoprotein E-deficient mice is independent of genetic alterations in plasminogen activator inhibitor-1. Arterioscler Thromb Vasc Biol 20(3):846-52. PubMed: 10712412MGI: J:61287
- Smith LH; Dixon JD; Stringham JR; Eren M; Elokdah H; Crandall DL; Washington K; Vaughan DE. 2006. Pivotal role of PAI-1 in a murine model of hepatic vein thrombosis. Blood 107(1):132-4. PubMed: 16160004MGI: J:126198
- Sullivan BP; Kassel KM; Jone A; Flick MJ; Luyendyk JP. 2012. Fibrin(ogen)-Independent Role of Plasminogen Activators in Acetaminophen-Induced Liver Injury. Am J Pathol 180(6):2321-9. PubMed: 22507835MGI: J:184692
- Tamura Y; Kawao N; Okada K; Yano M; Okumoto K; Matsuo O; Kaji H. 2013. Plasminogen activator inhibitor-1 is involved in streptozotocin-induced bone loss in female mice. Diabetes 62(9):3170-9. PubMed: 23715621MGI: J:208958
- Tamura Y; Kawao N; Yano M; Okada K; Matsuo O; Kaji H. 2014. Plasminogen activator inhibitor-1 deficiency ameliorates insulin resistance and hyperlipidemia but not bone loss in obese female mice. Endocrinology 155(5):1708-17. PubMed: 24605827MGI: J:210729
- Thomsen M; Woldbye DP; Wortwein G; Fink-Jensen A; Wess J; Caine SB. 2005. Reduced cocaine self-administration in muscarinic M5 acetylcholine receptor-deficient mice. J Neurosci 25(36):8141-9. PubMed: 16148222MGI: J:100892
- Tiwari N; Marudamuthu AS; Tsukasaki Y; Ikebe M; Fu J; Shetty S. 2016. p53- and PAI-1-mediated induction of C-X-C chemokines and CXCR2: importance in pulmonary inflammation due to cigarette smoke exposure. Am J Physiol Lung Cell Mol Physiol 310(6):L496-506. PubMed: 26747783MGI: J:232651
- Tucker TA; Jeffers A; Alvarez A; Owens S; Koenig K; Quaid B; Komissarov AA; Florova G; Kothari H; Pendurthi U; Mohan Rao LV; Idell S. 2014. Plasminogen activator inhibitor-1 deficiency augments visceral mesothelial organization, intrapleural coagulation, and lung restriction in mice with carbon black/bleomycin-induced pleural injury. Am J Respir Cell Mol Biol 50(2):316-27. PubMed: 24024554MGI: J:231868
- Wang H; Zhang Y; Heuckeroth RO. 2007. PAI-1 deficiency reduces liver fibrosis after bile duct ligation in mice through activation of tPA. FEBS Lett 581(16):3098-104. PubMed: 17561000MGI: J:123733
- Xu Z; Castellino FJ; Ploplis VA. 2010. Plasminogen activator inhibitor-1 (PAI-1) is cardioprotective in mice by maintaining microvascular integrity and cardiac architecture. Blood 115(10):2038-47. PubMed: 20009036MGI: J:158855
- Yamamoto K; Takeshita K; Shimokawa T; Yi H; Isobe K; Loskutoff DJ; Saito H. 2002. Plasminogen activator inhibitor-1 is a major stress-regulated gene: implications for stress-induced thrombosis in aged individuals. Proc Natl Acad Sci U S A 99(2):890-5. PubMed: 11792849MGI: J:73984
- Yan L; DeMars LC. 2014. Effects of a high-fat diet on spontaneous metastasis of Lewis lung carcinoma in plasminogen activator inhibitor-1 deficient and wild-type mice. PLoS One 9(10):e110869. PubMed: 25356654MGI: J:223539
- Yepes M; Sandkvist M; Coleman TA; Moore E; Wu JY; Mitola D; Bugge TH; Lawrence DA. 2002. Regulation of seizure spreading by neuroserpin and tissue-type plasminogen activator is plasminogen-independent. J Clin Invest 109(12):1571-8. PubMed: 12070304MGI: J:120679
- Zhu Y; Carmeliet P; Fay WP. 1999. Plasminogen activator inhibitor-1 is a major determinant of arterial thrombolysis resistance. Circulation 99(23):3050-5. PubMed: 10368124MGI: J:103348
- Zmijewski JW; Bae HB; Deshane JS; Peterson CB; Chaplin DD; Abraham E. 2011. Inhibition of neutrophil apoptosis by PAI-1. Am J Physiol Lung Cell Mol Physiol 301(2):L247-54. PubMed: 21622848MGI: J:176331
- von Montfort C; Beier JI; Kaiser JP; Guo L; Joshi-Barve S; Pritchard MT; States JC; Arteel GE. 2010. PAI-1 plays a protective role in CCl4-induced hepatic fibrosis in mice: role of hepatocyte division. Am J Physiol Gastrointest Liver Physiol 298(5):G657-66. PubMed: 20203062MGI: J:159243